Literature DB >> 20928905

Confirmation that the specific SSLP microsatellite allele 4qA161 segregates with fascioscapulohumeral muscular dystrophy (FSHD) in a cohort of multiplex and simplex FSHD families.

Gillian Spurlock1, Hoi-Ping Jim, Meena Upadhyaya.   

Abstract

The molecular defect in fascioscapulohumeral muscular dystrophy (FSHD) has proved difficult to explain. Although contraction within a polymorphic tandem repeat located at 4q35.2 is unequivocally associated with disease expression, the specific biological mechanism involved in the phenotype has yet to be resolved. Several studies have demonstrated that a specific 4q35.2-located haplotype (4qA161) is also closely associated with FSHD expression. Therefore, in this study we analyzed the haplotype association in a large cohort of sporadic and familial FSHD families from the UK. In all cases the affected individuals displayed the 4qA161 haplotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20928905     DOI: 10.1002/mus.21766

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

Review 1.  Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence.

Authors:  Silvère M van der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Trends Mol Med       Date:  2011-02-01       Impact factor: 11.951

2.  Identification of two novel SMCHD1 sequence variants in families with FSHD-like muscular dystrophy.

Authors:  Jincy Winston; Laura Duerden; Matthew Mort; Ian M Frayling; Mark T Rogers; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

Review 3.  Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?

Authors:  Mark Richards; Frédérique Coppée; Nick Thomas; Alexandra Belayew; Meena Upadhyaya
Journal:  Hum Genet       Date:  2011-10-09       Impact factor: 4.132

Review 4.  Deciphering transcription dysregulation in FSH muscular dystrophy.

Authors:  Melanie Ehrlich; Michelle Lacey
Journal:  J Hum Genet       Date:  2012-06-21       Impact factor: 3.172

5.  Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Rabi Tawil; John T Kissel; Chad Heatwole; Shree Pandya; Gary Gronseth; Michael Benatar
Journal:  Neurology       Date:  2015-07-28       Impact factor: 9.910

6.  Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2.

Authors:  Richard J L F Lemmers; Rabi Tawil; Lisa M Petek; Judit Balog; Gregory J Block; Gijs W E Santen; Amanda M Amell; Patrick J van der Vliet; Rowida Almomani; Kirsten R Straasheijm; Yvonne D Krom; Rinse Klooster; Yu Sun; Johan T den Dunnen; Quinta Helmer; Colleen M Donlin-Smith; George W Padberg; Baziel G M van Engelen; Jessica C de Greef; Annemieke M Aartsma-Rus; Rune R Frants; Marianne de Visser; Claude Desnuelle; Sabrina Sacconi; Galina N Filippova; Bert Bakker; Michael J Bamshad; Stephen J Tapscott; Daniel G Miller; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

Review 7.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 8.  Cellular and animal models for facioscapulohumeral muscular dystrophy.

Authors:  Alec M DeSimone; Justin Cohen; Monkol Lek; Angela Lek
Journal:  Dis Model Mech       Date:  2020-10-28       Impact factor: 5.758

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.